Timing clarification: Leidos has scheduled its Q2 earnings call for Tuesday, August 4, 2026, at 8:00 a.m. ET, with results released before the call. That is today, not tomorrow, based on the stated current date. The quarter ended July 3, 2026.
The central issue is not whether Leidos produces an especially strong Q2. Management already characterized Q2 as the likely low point of 2026 for both revenue growth and margins. The more important questions are:
The stock has already absorbed substantial skepticism. LDOS closed at $118.75 on August 3, down roughly 20% from May 4, while SPY rose approximately 6% over the same period. However, LDOS has rebounded about 19% from its June 25 low, so the setup is no longer completely washed out.
A merely in-line quarter accompanied by credible second-half commentary could be enough for a constructive reaction. Conversely, weak bookings, additional fixed-price charges, or any reduction in guidance would reinforce concerns that the expected acceleration is slipping.
Leidos entered Q2 following:
Management raised 2026 guidance after Q1 to:
| Metric | 2026 guidance |
|---|---|
| Revenue | $18.0–$18.4 billion |
| Adjusted EBITDA margin | Mid-13% range |
| Non-GAAP diluted EPS | $12.10–$12.50 |
| Operating cash flow | Approximately $1.8 billion |
Importantly, management said the guidance increases primarily reflected the Entrust acquisition, while the outlook for the legacy business remained largely unchanged.
Q1 also contained a $15 million insurance reimbursement that will not repeat in Q2. Meanwhile, contract estimate changes were a $9 million pretax headwind, including unfavorable revisions in Defense and Homeland.
I could not verify a reliable live analyst consensus from the available research database. The following are therefore analytical markers, not published consensus estimates.
| Metric | Analytical marker | What matters |
|---|---|---|
| Revenue | $4.3–$4.4 billion | Management said Q2 could be similar to Q1 or modestly lower |
| Adjusted EBITDA margin | Low-to-mid 13% range | Q2 was explicitly framed as the annual margin trough |
| Non-GAAP EPS | Approximately $2.85–$3.00 | Lower margin and no insurance benefit, partly offset by Entrust and buybacks |
| Book-to-bill | Around or above 1.0x | More important than a modest EPS beat |
| Full-year guidance | Reaffirmation expected | Quality of the second-half bridge will determine credibility |
Investors should not overreact to a modest sequential decline. Management directly warned that some Q1 revenue was pulled forward from Q2 and that near-term investments would increase.
A larger-than-expected decline—particularly revenue below roughly $4.25 billion or a material margin shortfall—would be more concerning because it would increase the burden on the second half.
Assuming Q2 revenue of approximately $4.35 billion, Leidos would need to generate average quarterly revenue of roughly:
That implies a meaningful step-up from the first-half run rate.
A similar issue applies to EPS. If Q2 non-GAAP EPS is around $2.90, Leidos would need average second-half EPS of approximately $3.04–$3.24 per quarter to achieve its annual range.
That is feasible if awards convert on schedule, Defense programs ramp and Entrust contributes a full quarter. But management needs to provide evidence rather than simply repeat that growth is coming.
Q1 revenue increased 7%, or 6% organically, with operating margin improving to 10.2% on a non-GAAP basis. Demand was supported by intelligence-community mission work, digital infrastructure and cyber capabilities.
Investors should look for:
This segment is important to counter the market view that government IT services will lose budget priority relative to hardware and weapons.
Q1 Health revenue was flat at $1.19 billion, while non-GAAP operating margin remained exceptionally strong at approximately 24%.
The main uncertainty is Veterans Benefits Administration exam volume following the addition of another provider. Management previously expected a modest 2026 reset but reported that Q1 volumes remained elevated.
Watch for:
Flat revenue with stable margins would likely be acceptable. A sharper volume decline or less confidence around VBA would be a negative because Health generates a disproportionate share of segment profit.
Entrust closed on March 27, meaning Q2 is the first quarter with a full contribution. The acquisition expands Leidos’ utility-engineering, grid-modernization and energy-infrastructure operations.
Q1 included only $11 million of reported Entrust revenue due to the late-March closing. Pro forma disclosure suggested approximately $128 million of incremental quarterly revenue had Entrust been owned for all of Q1, providing a rough indication of its scale.
Investors should focus on:
Homeland’s reported Q1 GAAP operating margin fell to 4%, partly because of $25 million in additional acquisition, integration and restructuring costs and fixed-price program issues. A cleaner view of underlying profitability would help.
Defense revenue was nearly flat in Q1, while non-GAAP margin fell to 8.3%. Management attributed the pressure partly to a scheduled delay on a fixed-price development program and expected profitability to improve as higher-quality production work ramps.
Key programs and opportunities include:
The company has discussed more than $9 billion of Defense awards over the previous 15 months and another $8 billion of pipeline opportunities.
The critical distinction is between an attractive long-term pipeline and actual near-term production revenue. Investors should seek:
Q1 book-to-bill was only 0.8x, although trailing-12-month book-to-bill remained healthy at 1.1x. Management expected awards to increase significantly over the remainder of the year.
A Q2 book-to-bill above 1.0x, particularly with strong funded bookings, would materially improve confidence in the second-half outlook. Another sub-1.0x quarter would make the promised acceleration harder to underwrite, even if EPS exceeds expectations through cost control.
Investors should also distinguish among:
These categories have very different revenue implications.
The Entrust acquisition increased debt to approximately $6.3 billion and gross leverage to 2.6x at the end of Q1. Leidos also had $300 million of commercial paper outstanding, which management intended to repay during 2026.
Despite the acquisition, Leidos repurchased $200 million of stock in Q1 and raised operating-cash-flow guidance to approximately $1.8 billion.
Points to watch:
Capex was only $31 million in Q1, so a substantial increase is likely if the company proceeds with production investments. Underspending could support near-term free cash flow but may also indicate that anticipated Defense ramps have been delayed.
Leidos plans to combine its Security Enterprise Solutions business with Analogic, retaining a 41.5% minority interest. The transaction was expected to close in the second half of 2026 and was not included in existing guidance.
Investors need an update on:
The JV, Entrust acquisition and Kudu acquisition are repositioning Leidos toward Defense technology, cyber, managed health and energy infrastructure. Management may be asked whether further divestitures or acquisitions are likely.
The most important bullish outcome would be evidence that Q2 was genuinely the trough and that second-half growth is already funded.
Given the stock’s decline since Q1, this could still produce a neutral-to-positive reaction, provided bookings are acceptable.
The largest downside risk is not a modest Q2 miss by itself; it is evidence that the anticipated second-half inflection has moved further out.
LDOS enters Q2 earnings with low near-term expectations but a demanding second-half guide. Management has already labeled the quarter a trough, so investors should emphasize bookings, funded backlog, Defense production timing and Entrust execution over small deviations from quarterly EPS.
The cleanest positive thesis is:
Q2 holds together, bookings improve, Entrust performs, and management provides a credible funded bridge to faster growth and higher earnings in Q3 and Q4.
The cleanest negative thesis is:
Q2 weakness proves deeper than expected, awards remain slow, and the full-year outlook requires an increasingly aggressive fourth-quarter recovery.
Given the stock’s significant underperformance since May, a controlled quarter and credible reaffirmation may be sufficient. But another quarter of weak bookings or unexpected contract charges would likely keep investors skeptical.
Research based on Leidos’ Q1 2026 earnings call and 10-Q, its July 7 earnings-call announcement, and stock-price data through August 3, 2026.